News Release: CRF Health’s TrialMax eCOA Solution Selected for Landmark Pain Outcomes Study by Global Japanese Pharmaceutical Company

CRF Health, the leading provider of patient-centered eSource for the life sciences industry, today announced that its TrialMax Touch® and TrialMax Slate® solutions have been selected by a Global Category Japanese Pharmaceutical company for a significant pain trial. The Phase III trial will involve 800 screened and 320 randomized subjects across 40 sites in the US.

CRF Health’s TrialMax Touch® delivers an easy-to-use smartphone solution to collect the primary endpoint data of the study via a daily diary. With home-based patients and daily diary entries, the high compliance afforded by electronic data capture vs. paper was a key requirement. The high-quality solution was selected by the sponsor for the benefits it brings, such as streamlining data collection through instant capture, rather than requiring patients to visit a site, and a high compliance rate which is achieved through the solutions’ notification reminders, intuitive interface and mobility.

For the investigators in the study, TrialMax Slate® will provide the ability to send reminders to keep patients engaged, while the dashboard clearly displays the questionnaire status of all patient visits. This reduces site burden and increases the efficiency of the eCOA collection process by highlighting required and incomplete questionnaires.

“In the area of pain therapy there are a lot of questionnaires completed by the patient at home and these are typically critical endpoints to the study,” commented Rachael Wyllie, CRF Health’s CEO. “With our proven track record and unparalleled eCOA expertise, CRF Health was selected as the best provider to ease patient and site burden and maximize the capture of critical data.”

For further information on CRF Health and the TrialMax eCOA solutions, please visit www.crfhealth.com.

This post was written by:

- who has written 2293 posts on mHealthWatch.


Contact the author

0 comments
Advert